Optipharm.CO.LTD
Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and c… Read more
Optipharm.CO.LTD (153710) - Total Liabilities
Latest total liabilities as of September 2025: ₩16.61 Billion KRW
Based on the latest financial reports, Optipharm.CO.LTD (153710) has total liabilities worth ₩16.61 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Optipharm.CO.LTD - Total Liabilities Trend (2015–2024)
This chart illustrates how Optipharm.CO.LTD's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Optipharm.CO.LTD Competitors by Total Liabilities
The table below lists competitors of Optipharm.CO.LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PDS Biotechnology Corp
NASDAQ:PDSB
|
USA | $25.25 Million |
|
Integra Indocabinet Tbk PT
JK:WOOD
|
Indonesia | Rp3.14 Trillion |
|
Cambuci S.A
SA:CAMB3
|
Brazil | R$85.66 Million |
|
S.Kijchai Enterprise Public Company Limited
BK:SKN
|
Thailand | ฿1.39 Billion |
|
MicroCloud Hologram Inc.
NASDAQ:HOLO
|
USA | $81.50 Million |
|
PPI Inc
KQ:062970
|
Korea | ₩8.29 Billion |
|
Crest Ventures Limited
NSE:CREST
|
India | ₹4.03 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Optipharm.CO.LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Optipharm.CO.LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Optipharm.CO.LTD (2015–2024)
The table below shows the annual total liabilities of Optipharm.CO.LTD from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩15.98 Billion | +13.11% |
| 2023-12-31 | ₩14.13 Billion | +16.10% |
| 2022-12-31 | ₩12.17 Billion | +19.17% |
| 2021-12-31 | ₩10.21 Billion | +35.43% |
| 2020-12-31 | ₩7.54 Billion | +23.42% |
| 2019-12-31 | ₩6.11 Billion | -15.07% |
| 2018-12-31 | ₩7.20 Billion | +1.97% |
| 2017-12-31 | ₩7.06 Billion | -0.27% |
| 2016-12-31 | ₩7.08 Billion | -46.06% |
| 2015-12-31 | ₩13.12 Billion | -- |